Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RAD 202

Next Previous
Search
Drug Profile

RAD 202

Alternative Names: RAD-202

Latest Information Update: 01 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Radiopharm Theranostics
  • Class Antineoplastics; Radioisotopes; Radiopharmaceuticals; Single-domain antibodies
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase 0 Solid tumours
  • Preclinical Breast cancer; Gastric cancer

Most Recent Events

  • 01 Apr 2025 Pharmacokinetics and adverse events data from a preclinical trial in Breast cancer released by Radiopharm Theranostics
  • 26 Feb 2025 Radiopharm Theranostics plans a phase 0 trial in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) (NCT06824155)
  • 12 Feb 2025 Phase-0 for Solid tumours (Late-stage disease, Second-line therapy or greater, Metastatic disease) in Australia (Parenteral) (NCT06824155)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top